Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Liposarcoma 1

Interventions

Vincristine 12Temozolomide 11Irinotecan 10Cyclophosphamide 10Melphalan 8Filgrastim 8Etoposide 7Ifosfamide 6Granulocyte Colony-Stimulating Factor 6Doxorubicin 6Vinorelbine 5Gemcitabine 5Busulfan 5Thiotepa 4Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Dactinomycin 4pegfilgrastim 3liposomal doxorubicin 3irinotecan sucrosofate 3fludarabine 3etoposide phosphate 3Stem Cell Transplantation 3Sirolimus 3Proton Therapy 3Cisplatin 3Carboplatin 3Bone Marrow Transplantation 3thymoglobulin 2regorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Rhabdomyosarcoma × silmitasertib × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡